Payment overview · 2025
General Payments
$4,747.63
115 reported records · 25 companies
Healthcare provider profile · identity verified
Timothy J Izzo, DO
Allopathic & Osteopathic Physicians|Family Medicine · GRAND LEDGE, MI · NPI 1720152846
Verified facts
What the public records show
CMS Open Payments records show Timothy J Izzo, DO received $4,747.63 in general payments during 2025 across 115 reported records.
Lilly USA, LLC accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $3,090.93 | 65.1% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.58 | 4.7% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $205.65 | 4.3% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $204.51 | 4.3% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.46 | 4.3% | 24 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $109.77 | 2.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $91.16 | 1.9% | 6 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $69.46 | 1.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $62.70 | 1.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.24 | 1.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.69 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $46.48 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.09 | 0.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.44 | 0.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38.14 | 0.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.83 | 0.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.75 | 0.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.71 | 0.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.05 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.48 | 0.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.29 | 0.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.17 | 0.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.07 | 0.4% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.91 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,400.00 | 1 |
| Food and Beverage | $1,808.16 | 111 |
| Travel and Lodging | $539.47 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $2,556.37 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $182.31 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $154.20 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $127.97 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.26 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $109.77 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $100.62 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $74.22 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $69.46 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.38 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $63.83 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.43 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $62.70 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $55.14 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.14 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.58 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.24 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.69 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $46.48 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.35 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.26 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.81 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.75 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $30.71 | 2 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.35 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.35 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $19.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $9.73 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $2.55 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $2.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 177 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 253 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
253 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
177 | 43 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1220 | 333 |
| Levothyroxine Sodium | Levothyroxine Sodium | 754 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 723 | 203 |
| Lisinopril | Lisinopril | 438 | 119 |
| Omeprazole | Omeprazole | 410 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 112 |
| Losartan Potassium | Losartan Potassium | 343 | 104 |
| Alprazolam | Alprazolam | 338 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 333 | 92 |
| Metformin Hcl | Metformin Hcl | 321 | 95 |
| Tramadol Hcl | Tramadol Hcl | 271 | 50 |
| Gabapentin | Gabapentin | 269 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 84 |
| Mounjaro | Tirzepatide | 253 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 235 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 207 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 202 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 196 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 54 |
| Eliquis | Apixaban | 177 | 43 |
| Simvastatin | Simvastatin | 175 | 45 |
| Sertraline Hcl | Sertraline Hcl | 168 | 39 |
| Trazodone Hcl | Trazodone Hcl | 168 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 57 |
| Montelukast Sodium | Montelukast Sodium | 150 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 38 |
| Meloxicam | Meloxicam | 148 | 52 |
| Temazepam | Temazepam | 146 | 20 |
| Ezetimibe | Ezetimibe | 139 | 45 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 138 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 62 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 132 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 34 |
| Jardiance | Empagliflozin | 121 | 33 |
| Allopurinol | Allopurinol | 117 | 32 |
| Bupropion Xl | Bupropion Hcl | 116 | 32 |
| Carvedilol | Carvedilol | 113 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 28 |
| Celecoxib | Celecoxib | 90 | 24 |
| Lorazepam | Lorazepam | 86 | 17 |
| Potassium Chloride | Potassium Chloride | 86 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 81 | 20 |
| Mirtazapine | Mirtazapine | 81 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Ibuprofen | Ibuprofen | 65 | 35 |
| Finasteride | Finasteride | 63 | 16 |
| Diazepam | Diazepam | 62 | 22 |
| Furosemide | Furosemide | 62 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 17 |
| Prednisone | Prednisone | 59 | 46 |
| Alendronate Sodium | Alendronate Sodium | 57 | suppressed |
| Lansoprazole | Lansoprazole | 56 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 16 |
| Myrbetriq | Mirabegron | 54 | 22 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 51 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 15 |
| Valsartan | Valsartan | 47 | 15 |
| Atenolol | Atenolol | 43 | 13 |
| Risedronate Sodium | Risedronate Sodium | 43 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 14 |
| Meclizine Hcl | Meclizine Hcl | 41 | 24 |
| Naproxen | Naproxen | 41 | 19 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Estradiol | Estradiol | 37 | 14 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Modafinil | Modafinil | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Nystatin | Nystatin | 33 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 11 |
| Azithromycin | Azithromycin | 31 | 30 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Prolia | Denosumab | 31 | 18 |
| Baclofen | Baclofen | 30 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Trulicity | Dulaglutide | 26 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Mirabegron Er | Mirabegron | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 11 |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 15 |
| Primidone | Primidone | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Belbuca | Buprenorphine Hcl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Novolog | Insulin Aspart | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Teriparatide | Teriparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,747.63 · 115 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AJOVY, Auvelity, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, ELIQUIS, ENFLONSIA, EVENITY, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, Hillrom - Cardiac Ambulatory Monitor, ID NOW INSTRUMENT, INGREZZA, ImmunoCAP, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TRUMENBA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VIBERZI, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error